Today's top medical abstracts
Rheumatology
Become a Member Today!
Email
Password
Remember me
Forgot your Password?

Invite Code?

Home
General Rheumatology
For Practicing
Rheumatologists
Conferences
Jobs
Newsletters
My Library
Topics in
Rheumatology
        Amyloidosis
        Autoimmune/Heritable
        Basic Science/Genetics
        Bone Metabolism
        Chr Fatigue/Fibromyalgia
        Clinical Pharmacology
        Connective Tissue Dz
        Diagnostics/Radiology
        Economics of Medicine
        Gout and Hyperuricemia
        Infectious Arthritis
        Osteoarthritis
        Other Arthritis
        Pediatric Rheumatology
        Popular Press
        Rheumatoid Arthritis
        Spondylarthropathies
        Systemic Lupus (SLE)
        Vasculitic Syndromes
 
Help
Resource Center
RSS News Feeds
Send Newsletter
to a Friend
 
Sponsor
For Practicing Rheumatologists
Today's Rheumatology News: dnaJP1, A New Oral Treatment For RA
D Scott Cunningham MD, PhD, MDLinx Oncology
Today's Rheumatology News: FDA Approves Actemra
D Scott Cunningham MD, PhD, MDLinx Rheumatology
From the Editors: New Clinical-Only Option for MDLinx!
Stephen Smith, MDLinx
  See all
Article Summary

Click the title below to leave the MDLinx Network and go to the Journal's Website
Tumor necrosis factor-α antagonist use and heart failure in elderly patients with rheumatoid arthritis
American Heart Journal, 07/01/08
Print     Email This Article     Save in My Library   Free Abstract
Setoguchi S et al. – TNF-α antagonists (TNFAs) may increase the risk of both first hospitalization and exacerbation of heart failure (HF) in elderly patients with RA; larger and more detailed studies are needed to confirm the findings.

Methods
  • Aim was to determine if TNFAs pose an increased risk of HF in older pts with RA
  • Data from Medicare and drug benefit programs in 2 states
  • RA pts aged ≥65, who received TNFA or MTX
  • The cohort was divided into pts with and w/o previous HF
  • Demographic variables, cv risk factors, RA severity-related measures, and other comorbidities were considered
  • The primary end point was hospitalization with HF
  • Adjusted effect of TNFAs on HF hospitalization was estimated

Results
  • 1,002 TNFA users and 5,593 MTX users
  • 59 HF admissions during 1,680 person-years of TNFA use; 227 HF admissions during 10,623 person-years of MTX use
  • Adjusted hazard ratio for HF hospitalization was 1.70
  • Similar results were found in pts with and w/o previous HF
  • Among pts with previous HF, the adjusted hazard ratio for death was 4.19

 

--- BASIC SCIENCE/GENETICS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

--- CLINICAL PHARMACOLOGY TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



 

Sponsor
--- RHEUMATOID ARTHRITIS TOP ARTICLES ---

Receive free subspecialty "5-minute updates" via email



Read a Different Specialty
Allergy/Immunology
Anesthesiology
Cardiology
Dermatology
Drugs
Emergency Medicine
Endocrinology
ENT
Family Medicine
Gastroenterology
Hematology-Oncology
Infectious Disease
Internal Medicine
Nephrology
Neurology
OB/Gyn
Ophthalmology
Orthopedics
Pediatrics
Psychiatry
Pulmonology
Radiology
Rheumatology
Surgery
Urology
Profession Index
Dentist
Hospital Administrator
Nurse
    Medical Students
Nurse Practitioner
Pharma/Drug Marketer
    Pharmacist
Physician
Physician Assistants
Article Search
Keyword:
Search:
Published within:
Sort By:
Date Relevance
    
About MDLinx  |  Contact  |  Advertise with MDLinx  |  Site Map  |  Privacy Policy  |  Terms of Use  |  Sign Up For Newsletters  |  Recommend this Site

English |  Español |  Français |  Deutsch |  中文 |  Руccкий |  Norsk |  Nederlands |  Português |  Italiano

©1999-2008 MDLinx, Inc.